Genenta Science

Genenta Science, a clinical-stage biotechnology firm, was established in Milan, Italy, in July 2014 as a spin-off from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget). The company was co-founded by Pierluigi Paracchi, who serves as the CEO, and Luigi Naldini, M.D., Ph.D., the director of SR-Tiget, alongside Bernhard Gentner, M.D. Paracchi brings a background in finance and investment, having managed a venture capital fund before co-founding Genenta, providing the company with strategic financial direction from its inception. Naldini and Gentner contribute deep scientific expertise in gene and cell therapy, with Naldini being a recognized pioneer in the development of lentiviral vectors for gene transfer.

The company is focused on developing hematopoietic stem cell gene therapies for the treatment of solid tumors. Its core technology is centered on engineering hematopoietic stem and progenitor cells (HSPCs) to deliver immunomodulatory molecules directly into the tumor microenvironment. This approach is designed to re-program the tumor's surroundings, which typically suppress the immune system, to instead trigger a powerful and sustained anti-cancer immune response. The lead product candidate, Temferon™, utilizes this platform to express interferon-alpha (IFN-α), a potent anti-cancer agent, specifically within the tumor, thereby aiming to minimize the systemic toxicity often associated with conventional interferon treatments.

Genenta operates within the oncology and biotechnology markets, targeting a significant unmet need in the treatment of solid tumors, particularly glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. Its business model is typical of a clinical-stage biotech company, centered on research and development funded by venture capital and public offerings. A major financial milestone was achieved in December 2021 when the company went public on the Nasdaq stock exchange under the ticker symbol "GNTA". The ultimate goal is to bring its therapeutic products to market, which would generate revenue through sales and licensing agreements with larger pharmaceutical partners. The company's unique selling proposition lies in its targeted delivery system, which has the potential to make immunotherapy effective against "cold" tumors that do not typically respond to existing treatments like checkpoint inhibitors.

Keywords: gene therapy, oncology, biotechnology, solid tumors, cancer immunotherapy, hematopoietic stem cells, lentiviral vectors, clinical-stage, glioblastoma, Temferon